Compliance Achievement: Social media commentary highlights Outlook Therapeutics regaining Nasdaq listing compliance after maintaining a share price above $1 for ten consecutive sessions. This step eliminates an immediate overhang and shifts attention toward operational priorities.
Pipeline Momentum: Observers note updates to the company's website showcasing an expanded pipeline, including multiple Phase 3 programs in ophthalmology indications such as DME and BRVO. Traders reference ongoing clinical progress as a potential driver for near-term activity ahead of regulatory milestones.
Regulatory Review Focus: Attention centers on the scheduled July 29 FDA review of the biologics license application for ONS-5010 in wet age-related macular degeneration. Participants describe this event as a pivotal catalyst that could reshape the company's commercial outlook.
Note: This discussion summary was generated from an AI condensation of post data.
Outlook Therapeutics Insider Trading Activity
Outlook Therapeutics insiders have traded $OTLK stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OTLK stock by insiders over the last 6 months:
- GHIATH M. SUKHTIAN purchased 8,539,709 shares for an estimated $4,999,999
- KURT J HILZINGER purchased 400,000 shares for an estimated $176,520
- FAISAL GHIATH SUKHTIAN purchased 122,174 shares for an estimated $50,005
- YEZAN MUNTHER HADDADIN has made 2 purchases buying 63,000 shares for an estimated $39,105 and 0 sales.
- RANDY H THURMAN purchased 5,000 shares for an estimated $2,145
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Outlook Therapeutics Revenue
Outlook Therapeutics had revenues of $127.4K in Q2 2026.
You can track OTLK financials on Quiver Quantitative's OTLK stock page.
You can access data on OTLK stock through the Quiver Quantitative API.
Outlook Therapeutics Hedge Fund Activity
We have seen 29 institutional investors add shares of Outlook Therapeutics stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 4,168,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $857,774
- SCHONFELD STRATEGIC ADVISORS LLC removed 2,441,355 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $502,430
- COMMONWEALTH EQUITY SERVICES, LLC added 357,500 shares (+317.8%) to their portfolio in Q1 2026, for an estimated $73,573
- MARSHALL WACE, LLP removed 298,456 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $61,422
- GEODE CAPITAL MANAGEMENT, LLC added 287,142 shares (+90.7%) to their portfolio in Q1 2026, for an estimated $59,093
- WARBERG ASSET MANAGEMENT LLC added 275,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $56,595
- RENAISSANCE TECHNOLOGIES LLC added 255,157 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,511
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Outlook Therapeutics Price Targets
Multiple analysts have issued price targets for $OTLK recently. We have seen 3 analysts offer price targets for $OTLK in the last 6 months, with a median target of $1.0.
Here are some recent targets:
- Edward Woo from Ascendiant Capital set a target price of $10.0 on 06/11/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $0.5 on 02/18/2026
- Daniil Gataulin from Chardan Capital set a target price of $1.0 on 02/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
